Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,335,320

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,335,320
Title:Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed ##STR00001##
Inventor(s): Ebens, Jr.; Allen J. (San Carlos, CA), Friedman; Lori (San Carlos, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:13/968,202
Patent Claims:1. A method for selecting compounds to be used in combination for the treatment of an hematopoietic malignancy comprising: a) administering synergistic effective amounts of a therapeutic combination of a compound selected from Formula Ia: ##STR00056## and a chemotherapeutic agent selected from dexamethasone, thioTEPA, doxorubicin, vincristine, rituximab, cyclophosphamide, prednisone, melphalan, lenalidomide, bortezomib, rapamycin, and cytarabine to tumor cells; b) measuring a decrease in p-Akt levels; and c) selecting a synergistic therapeutic combination for the treatment of the hematopoietic malignancy which shows a decrease in p-Akt levels.

2. The method of claim 1 wherein the decrease in p-Akt level is determined by reduction of p-AKT, p-S6RP, p-Bad, or beta-actin.

3. The method of claim 1 wherein the hematopoietic malignancy is selected from non-Hodgkin's lymphoma, diffuse large hematopoietic lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia (CLL), multiple myeloma, acute myeloid leukemia (AML), and myeloid cell leukemia (MCL).

4. The method of claim 1 wherein the chemotherapeutic agent is rituximab.

Details for Patent 9,335,320

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   See Pricing Genentech, Inc. (South San Francisco, CA) 2036-05-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.